EGF mutant receptor vIII as a molecular target in cancer therapy.
about
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaUpdate on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancerCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewMolecular Targeted Therapies of Aggressive Thyroid CancerVaccine therapies in malignant gliomaMolecular recognition of gangliosides and their potential for cancer immunotherapiesCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkTargeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaMechanisms of action of therapeutic antibodies for cancerMutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panelQuantification and kinetic analysis of Grb2-EGFR interaction on micro-patterned surfaces for the characterization of EGFR-modulating substancesGold Nanotheranostics: Proof-of-Concept or Clinical Tool?Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.RNA interference and nonviral targeted gene therapy of experimental brain cancerInference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM.Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and scienceEGFRvIII-targeted vaccination therapy of malignant glioma.Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.Role of receptor tyrosine kinases and their ligands in glioblastoma.Tissue-specific gene expression templates for accurate molecular characterization of the normal physiological states of multiple human tissues with implication in development and cancer studiesKinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours.Convergence between Wnt-β-catenin and EGFR signaling in cancer.Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.Selective cell death mediated by small conditional RNAsTargeting the EGFR signaling pathway in cancer therapy.Kinase-mediated quasi-dimers of EGFRComputational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.The development of immunotherapies for non-small cell lung cancer.Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIIEpidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells.mTORC1 phosphorylates UVRAG to negatively regulate autophagosome and endosome maturation.DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.The future of high-grade glioma: Where we are and where are we going.Identification of kinases and regulatory proteins required for cell migration using a transfected cell-microarray system.
P2860
Q24615166-D07F3EA2-08BE-4AA7-9203-C1E36B27CDC1Q24801944-E0075A66-18C8-4B0D-991A-0A323D681E53Q26740067-9281E549-2BCD-4D3D-B3A0-A81568F0F3EDQ26774734-54BF46B5-2F14-493C-A252-68492956D1FBQ26829328-70D3EC77-627D-4725-8EB1-403242DDD4ADQ26830588-806F893A-8FB6-4348-A796-551382E3894CQ26865911-96E812D7-16E4-4DD1-BB78-DDB6C5103124Q27010580-9932A5A4-2AD6-4CF1-A7D3-FB2575CF9BB3Q27853131-82679DCA-A95F-46C7-9786-9D5FAF6159F7Q28069900-EB3F32BD-67EA-45DE-8049-B9F7F7F9E46DQ28385366-5FC0330E-12A3-4420-A57B-2A16C8ABE801Q28484396-75BABC33-6F63-48B6-B3CA-9EACC9E99E3EQ28541305-E63EACDC-94CE-4081-AFAB-FEF8FF502D40Q30360668-E12C0287-83DF-4769-9D73-8A19097903E7Q33289414-EF169EF5-D2A8-486A-B9D3-986F73BB8BE8Q33523195-0732EAC4-FE79-4802-934F-7B38EBDA2080Q33569727-1FBC1553-F753-4E01-9856-E0FB494D12E6Q33597322-3BF024B6-6909-4D22-87AD-01394CA7F615Q33688619-F847CE3F-A671-461B-A366-AA2517399BF9Q33721106-0A1527B2-3C76-44F7-BC37-BAFE5B9A86C5Q33746514-3AA62394-5754-4C95-B15F-23AFD593D76EQ33758459-0CEA2E72-379A-4E3C-87A9-37DF8C77231DQ33809397-5DA0636C-E2ED-4271-B9AC-154A4AC77F87Q33883849-22FB7D47-4F06-42B7-A8D8-55D112BA97FBQ34006509-C0D4905D-57D7-4B72-8069-6E900186A148Q34112887-8AEE2B52-32B7-4F28-A16C-CABBC1EB5D5CQ34149071-28AEDF1A-DF9A-4276-86B5-F217568E2EBCQ34152633-EB2B23DB-6873-4054-8992-9362A6772027Q34165425-AAD07BA8-4E99-41F6-BE95-A0C705921516Q34246558-0BB5B510-2470-407D-B42E-05A15176327EQ34352792-18BE0920-8450-4898-9F18-977CC2067583Q34473476-6E80F41A-8132-4B36-9039-993A4902B19AQ34560660-1F0A3C19-B86C-4742-AA6F-A68B45C5C827Q34568677-D2DBEC5A-361B-426D-9152-4969BF1D630AQ34589789-08288F60-6028-428C-BB4E-C8F54EF07A64Q34654908-C746641B-1954-4D3F-8B84-6CEC819E5566Q35007765-E6D3DC8C-AE14-4E27-9A9E-D96F1DDA8EE4Q35059032-9F063B12-8193-4868-ACB7-187E7C2BD33BQ35114090-3EBBC92B-ADBE-4AF1-865A-B7CA07B3089FQ35194120-F67E7C24-F322-4664-B6C6-90450CAA6602
P2860
EGF mutant receptor vIII as a molecular target in cancer therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
EGF mutant receptor vIII as a molecular target in cancer therapy.
@ast
EGF mutant receptor vIII as a molecular target in cancer therapy.
@en
type
label
EGF mutant receptor vIII as a molecular target in cancer therapy.
@ast
EGF mutant receptor vIII as a molecular target in cancer therapy.
@en
prefLabel
EGF mutant receptor vIII as a molecular target in cancer therapy.
@ast
EGF mutant receptor vIII as a molecular target in cancer therapy.
@en
P356
P1476
EGF mutant receptor vIII as a molecular target in cancer therapy.
@en
P2093
P356
10.1677/ERC.0.0080083
P577
2001-06-01T00:00:00Z